| 证券代码：603976 | 证券简称：正川股份 | 公告编号：2026-004 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重庆正川医药包装材料股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、可转债发行上市概况 （一）可转债发行情况 经上海证券交易所自律监管决定书[2021]224号文同意，公司4.05亿元可转 换公司债券已于2021年6月1日起在上海证券交易所挂牌交易，债券简称"正川转 债"，债券代码"113624"。 （三）可转债转股价格调整情况 根据《上海证券交易所股票上市规则》和《重庆正川医药包装材料股份有限 公司公开发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）的约定， 公司该次发行的"正川转债"自可转换公司债券发行结束之日起满 6 个月后的第 一个交易日，即 2021 年 11 月 8 日起可转换为公司 A 股普通股，初始转股价格为 46.69 元/股，最新转股价格为 20. ...

Core Viewpoint - The article discusses the development and regulatory landscape of the pet chip industry in China, highlighting the importance of pet chips for pet management and public safety, as well as the evolving policies at both national and local levels [1][5][7]. Policy Development Timeline - The pet chip industry in China began pilot programs in 2010, focusing on dog management to address issues like urban dog population statistics and rabies prevention. By 2019, many regions implemented dog management regulations that emphasized the use of electronic identification (pet chips) [3]. - In 2024, Shenzhen's regulations mandate that all dogs, except for certain exceptions, must be implanted with electronic tags, reinforcing the importance of pet chips in public safety and management [3][9]. National Policy Summary - Currently, there are no direct national policies specifically targeting the pet chip industry; it falls under the broader pet economy sector. However, relevant regulations include customs announcements that require pets to be microchipped for identification when entering the country [5][6]. - Key national policies include the "Pet Feed Labeling Regulations" and "Pet Feed Hygiene Regulations," which aim to standardize pet food labeling and hygiene standards [6]. Local Policy Summary - Several provinces, including Shandong, Guangdong, Chongqing, Fujian, and Guizhou, have implemented mandatory pet chip implantation policies. For instance, Shandong's regulations require all registered dogs to have electronic chips as identification [7][9]. - Guangdong's regulations specify that all dogs must be microchipped and registered, with detailed management protocols established for pet ownership [9][10]. Development Goals - The regulations aim to standardize dog management, ensure public health and safety, and maintain social order. Local governments are actively promoting the pet chip industry to enhance pet management practices [12][13].

Core Viewpoint - The recent developments of Zhengchuan Co., Ltd. (stock code: 603976) include the approval of a convertible bond issuance, a forecasted decline in 2025 performance, and progress in international expansion efforts [1]. Group 1: Convertible Bond Issuance - The company received approval from the China Securities Regulatory Commission on February 1, 2026, to publicly issue convertible bonds with a total face value of 405 million yuan, with a term of 6 years [2]. - The funds raised will be used for the production of borosilicate pharmaceutical glass and compatibility research projects [2]. Group 2: Performance Forecast - On January 29, 2026, the company announced a performance forecast, estimating a net profit attributable to shareholders of 18 million to 24 million yuan for 2025, representing a year-on-year decrease of 54.93% to 66.2% [3]. - The decline in performance is primarily attributed to the impact of pharmaceutical procurement policies and intensified market competition [3]. Group 3: Subsidiary Development - The company's Hong Kong subsidiary, Zhengchuan International (Hong Kong) Co., Ltd., completed its registration in November 2025, which may facilitate the expansion into overseas markets [4].

Core Insights - The global pet chip market is experiencing significant growth, driven by increasing demand for pet identification and recovery solutions, with a projected market size of approximately 4.6 billion yuan in 2024 and expected to exceed 10.5 billion yuan by 2030 [7][10]. Group 1: Global Pet Chip Frequency Composition - The frequency composition of global pet chips is highly concentrated, with 134.2 kHz being the dominant frequency, accounting for 81% of the market, followed by 125 kHz at 16%, and 128 kHz at only 3% [1]. Group 2: Global Pet Chip Implantation Rate - North America leads in pet chip implantation rates at 80%, attributed to a mature pet management system and legislative requirements for chip implantation, while China has a low rate of less than 5% due to the absence of national mandates and awareness issues among pet owners [3]. Group 3: Proportion of Implanted Chips in Dogs vs. Cats - Globally, the proportion of implanted chips in dogs is generally higher than in cats, with dogs making up 90% of implanted pets in China, compared to only 10% for cats. This disparity is influenced by pet management regulations and the activity levels of different pet types [6]. Group 4: Global Pet Chip Market Size - The global pet chip market is projected to reach approximately 4.6 billion yuan by 2024, driven by regulatory changes and increased awareness among pet owners regarding the benefits of chip implantation [7]. Group 5: Future Market Size Forecast - The global pet chip market is expected to grow rapidly from 2025 to 2030, with a compound annual growth rate (CAGR) of 15%, leading to a market size exceeding 10.5 billion yuan by 2030 [10].

Core Viewpoint - Chongqing Zhengchuan Pharmaceutical Packaging Materials Co., Ltd. expects a significant decline in net profit for the year 2025, with projections indicating a decrease of 54.93% to 66.20% compared to the previous year [2][4]. Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders of between 18 million to 24 million yuan for 2025, a reduction of 29.25 million to 35.25 million yuan from the previous year [2][4]. - The expected net profit, excluding non-recurring gains and losses, is projected to be between 11 million to 16 million yuan, reflecting a decrease of 33.29 million to 38.29 million yuan year-on-year [2][4]. Group 2: Previous Year’s Performance - In the previous year, the total profit was 60.21 million yuan, with a net profit attributable to shareholders of 53.25 million yuan, and a net profit excluding non-recurring gains and losses of 49.29 million yuan [6]. Group 3: Reasons for Performance Decline - The decline in performance is attributed to multiple factors, including the deepening of pharmaceutical procurement policies, reforms in medical insurance payments, and intensified competition in the pharmaceutical market, leading to fluctuations in market demand from downstream customers, a decrease in product prices, and a reduction in sales volume [6].

Group 1 - The company Zhengchuan Co., Ltd. forecasts a net profit attributable to shareholders of 18 million to 24 million yuan for the year 2025, representing a decrease of 29.2488 million to 35.2488 million yuan compared to the previous year, which is a year-on-year decline of 54.93% to 66.2% [1] - The primary reasons for the performance change include the deepening of pharmaceutical procurement policies, healthcare payment reforms, and intensified competition in the pharmaceutical market, leading to fluctuations in market demand from downstream customers, a decline in product prices, and a reduction in product sales, which resulted in decreased operating revenue and a year-on-year decline in gross profit [1]

Core Viewpoint - Zhengchuan Co., Ltd. (603976.SH) expects a significant decline in net profit for the year 2025, primarily due to various market pressures and policy changes affecting the pharmaceutical industry [1] Financial Performance - The company anticipates a net profit attributable to shareholders of between 18 million to 24 million yuan for 2025, representing a decrease of 29.2488 million to 35.2488 million yuan compared to the previous year, which is a year-on-year decline of 54.93% to 66.20% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 11 million to 16 million yuan, reflecting a decrease of 33.2942 million to 38.2942 million yuan year-on-year, equating to a decline of 67.54% to 77.69% [1] Market Conditions - The anticipated decline in performance is attributed to the deepening of pharmaceutical procurement policies, reforms in medical insurance payments, and intensified competition in the pharmaceutical market [1] - Fluctuations in market demand from downstream customers, price reductions for certain products, and a decrease in product sales are contributing factors to the expected decline in operating revenue and gross profit [1]

Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2025 to be between 18 million and 24 million yuan, a decrease of 29.25 million to 35.25 million yuan compared to the previous year, representing a decline of 54.93% to 66.20%[3]. - The projected net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 11 million and 16 million yuan, down by 33.29 million to 38.29 million yuan year-on-year, reflecting a decrease of 67.54% to 77.69%[5]. - The total profit for the previous year was 60.21 million yuan, with a net profit attributable to shareholders of 53.25 million yuan and a net profit after deducting non-recurring gains and losses of 49.29 million yuan[6]. Factors Affecting Performance - The decline in performance is attributed to multiple factors including the deepening of pharmaceutical procurement policies, medical insurance payment reforms, and intensified market competition, leading to fluctuations in downstream customer demand and a decrease in product prices and sales volume[7]. Earnings Forecast Reliability - The earnings forecast is based on preliminary calculations by the company's finance department and has not been audited by registered accountants[8]. - The company emphasizes that there are no significant uncertainties affecting the accuracy of this earnings forecast[8]. - Investors are advised to pay attention to investment risks as the data provided is preliminary and the final financial figures will be disclosed in the official 2025 annual report[9].

Overview - The company has approved the use of idle self-owned funds for cash management to enhance fund utilization efficiency and increase returns for the company and its shareholders [2][3]. Cash Management Details - The total investment amount for this cash management initiative is 150 million RMB [4]. - The funds used for this cash management are entirely sourced from idle self-owned funds [5]. - The cash management product is a structured deposit from Chongqing Bank, with a term of 365 days [7]. Product Specifications - The structured deposit has a guaranteed minimum return of 1.50% and a floating return of either 0.55% or 0.75% [8]. - The product's start date is January 7, 2026, and it will mature on January 7, 2027 [8]. - The product is linked to the EUR/USD exchange rate, with specific conditions determining the actual annualized return [8]. Risk Control Measures - The company will select investment products that are high in safety, good in liquidity, and of medium to low risk [6][9]. - Independent directors have the authority to supervise and audit the use of funds, ensuring compliance with regulations [10]. - The company will monitor the progress of cash management closely and take necessary actions to ensure fund safety [10]. Impact on the Company - The cash management initiative will not affect the company's normal operational cash flow or its main business development [13]. - Utilizing idle self-owned funds for cash management is expected to improve fund efficiency and create better returns for the company and its shareholders [13]. Decision-Making Process - The board of directors and the supervisory board approved the cash management proposal on June 4, 2025, allowing for a maximum daily balance of 300 million RMB to be used for cash management within a 12-month rolling period [15].

| 证券代码：603976 | 证券简称：正川股份 | 公告编号：2026-002 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重庆正川医药包装材料股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 履行的审议程序：重庆正川医药包装材料股份有限公司（以下简称"公 司"）于2025年6月4日召开了第四届董事会第二十二次会议、第四届监事会第十 五次会议，审议通过了《关于使用闲置自有资金进行现金管理的议案》，同意公 司使用单日最高余额不超过人民币30,000万元的闲置自有资金进行现金管理，以 上资金额度在董事会审议通过之日起12个月内可以循环滚动使用。具体内容详见 公司于2025年6月5日在上海证券交易所网站（www.sse.com.cn）及指定信息披露 媒体上披露的《关于使用闲置自有资金进行现金管理的公告》（公告编号： 2025-031）。 一、本次现金管理概况 （三）资金来源 本次现金管理的资金 ...